Press Releases

CompChem Solutions enters Collaboration with Molecular Forecaster Inc

Molecular Forecaster Inc’s IMPACTS software predicts Cyp450 metabolic liabilities using a combination of 3D docking to metabolic enzymes, transition state modelling and rule-based approaches to predict sites of metabolism. Cyp oxidation sites, inhibition and substrate activity can be predicted. CompChem Solutions has entered into a collaboration with MFI to enable application of their technology to CompChem Solutions’ research programmes with clients. Contact us for further information.

In Press: NCE patent applications with US partner

Two NCE patent applications are currently being filed by a US partner for discovery of new therapeutic agents, where Susan Boyd of CompChem Solutions will be a named inventor on the patents, having conducted extensive modelling to assist in the discovery of these agents. Watch this space for further details when they can be released!

New publication on PGK1/DJ1 for modulation of telomere homeostasis

Our work with CRUK scientists in London and Glasgow on development of a ligand which appears to interact with the PGK1/DJ1 complex and to therefore modulate metabolic stress-induced telomere homeostasis has recently been published.

CompChem Solutions Ltd teams up with Collaborative Drug Discovery

CompChem Solutions Ltd is delighted to have become an Advocate partner for Collaborative Drug Discovery (CDD).   CDD offer a modern approach to research informatics, with their Vault application hosting a secure biological & chemical database platform which is simple to use and ideally positioned for use by small and large drug discovery teams alike.  Contact us for further information.

Susan Boyd receives CIR (French Research Tax Credit) Accreditation

Dr Susan Boyd, of CompChem Solutions & IOTA Pharmaceuticals Ltd, has received CIR accreditation for a three-year period from the French Ministry of Higher Education and Research. The French R&D tax credit initiative (“Crédit d’Impôt Recherche”, CIR) gives eligible research-based French companies, who are subject to corporate tax in France, the ability to claim tax relief of up to 30% on costs generated in R&D activities outsourced to Susan Boyd. We are extremely pleased to have received this approval from the French Ministry of Research since it will provide greater opportunities to support current and future customers in this important European market.